Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Bristol-Myers Squibb Co - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
BMY
New York
2834
https://www.bms.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Bristol-Myers Squibb Co
UPDATE 2-Bristol Myers' bowel disease drug fails in late-stage study
- Mar 28th, 2024 8:20 pm
Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…
- Mar 28th, 2024 8:05 pm
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
- Mar 28th, 2024 8:01 pm
Is Bristol Myers Squibb Stock a Buy?
- Mar 28th, 2024 12:15 pm
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
- Mar 28th, 2024 11:30 am
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
- Mar 27th, 2024 9:50 pm
20 Countries with the Highest Heart Disease Deaths Per Capita
- Mar 26th, 2024 11:19 am
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
- Mar 26th, 2024 10:59 am
Bristol-Myers Squibb Company (BMY) Impacted by Delay in New Product Launches
- Mar 25th, 2024 12:21 pm
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
- Mar 25th, 2024 12:00 pm
Bristol-Myers Squibb (NYSE:BMY) Has Announced A Dividend Of $0.60
- Mar 22nd, 2024 7:01 pm
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
- Mar 21st, 2024 9:50 pm
New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
- Mar 21st, 2024 7:00 pm
Bristol Myers (BMY) Gets EC Nod for Abecma's Label Expansion
- Mar 21st, 2024 11:53 am
Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
- Mar 20th, 2024 8:45 pm
UPDATE 2-Bristol Myers' Opdivo-Yervoy combo meets main goal in liver cancer trial
- Mar 20th, 2024 11:29 am
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
- Mar 20th, 2024 10:59 am
Bristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in "SO, Have You Found It?" Campaign
- Mar 19th, 2024 10:59 am
James D. Robinson III, Who Tried to Diversify American Express Far Beyond Cards, Dies at 88
- Mar 18th, 2024 11:32 pm
Bristol Myers' (BMY) Abecma Gets ODAC Votes for Label Expansion
- Mar 18th, 2024 1:31 pm
Scroll